Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.15 USD | +4.87% | +18.58% | +55.23% |
May. 14 | Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target | MT |
Apr. 12 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
Business Summary
Number of employees: 284
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Small Molecule and Cell Therapies
100.0
%
| 39 | 100.0 % | 77 | 100.0 % | +99.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 39 | 100.0 % | 77 | 100.0 % | +99.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Arthur Sands
CEO | Chief Executive Officer | 62 | 14-09-17 |
Hans van Houte
DFI | Director of Finance/CFO | 58 | 14-12-31 |
Chief Tech/Sci/R&D Officer | - | 21-08-31 | |
Paula O’Connor
CTO | Chief Tech/Sci/R&D Officer | - | 22-08-31 |
Gwenn Hansen
CTO | Chief Tech/Sci/R&D Officer | 53 | 14-12-31 |
Christine Ring
CMP | Compliance Officer | 59 | 19-08-31 |
Silinda Neou
IRC | Investor Relations Contact | - | 22-07-31 |
Public Communications Contact | - | 20-07-12 | |
Raf Lambrecht
LAW | General Counsel | - | 20-03-31 |
Michael T. Lotze
PRN | Corporate Officer/Principal | - | 20-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Judith Reinsdorf
BRD | Director/Board Member | 60 | 21-09-30 |
Paul Silva
BRD | Director/Board Member | 58 | 21-09-30 |
Arthur Sands
CEO | Chief Executive Officer | 62 | 14-09-17 |
Julia Gregory
BRD | Director/Board Member | 71 | 19-07-31 |
Lori Kunkel
BRD | Director/Board Member | 66 | 19-06-30 |
David Lacey
CHM | Chairman | 71 | 16-03-31 |
Edward Saltzman
BRD | Director/Board Member | 69 | 22-09-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 59,303,621 | 58,012,442 ( 97.82 %) | 0 | 97.82 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.22% | 913M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.58% | 22.28B | |
-11.90% | 22.41B | |
-5.34% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- NRIX Stock
- Company Nurix Therapeutics, Inc.